NasdaqGS - Nasdaq Real Time Price USD

Vor Biopharma Inc. (VOR)

0.2343

+0.0344

+(17.21%)

At close: June 2 at 4:00:00 PM EDT

0.2349

+0.00

+(0.26%)

Pre-Market: 4:44:49 AM EDT

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value. These strategic alternatives could include, among other alte

GlobeNewswire 25 days ago

VOR
+17.21%
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 2 months ago

VOR
+17.21%
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025$55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full y

GlobeNewswire 2 months ago

VOR
+17.21%
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT) clinical trialsDespite the increased time required to obtain informed consent, 100% of those surveyed continue to offer patients these innovative investigational treatment options CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company

GlobeNewswire 3 months ago

VOR
+17.21%
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference. Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceFireside Chat: Wednesday, February 12th at 12:00pm ET Location: Virtual A live webcast and archived replay of the fireside chat will be avail

GlobeNewswire 3 months ago

VOR
+17.21%
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross

Is it a good or bad thing when a stock experiences a golden cross technical event?

Zacks 4 months ago

VOR
+17.21%
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio’s Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Ho

GlobeNewswire 4 months ago

VOR
+17.21%
Vor Biopharma Secures $55.6M for Cancer Therapy Trials

The latest announcement is out from Vor Biopharma ( (VOR) ). Vor Biopharma has entered into a Securities Purchase Agreement for a $55.6 million private placement to issue shares and warrants, with the proceeds intended to fund clinical and preclinical development and extend cash runway through 2025. The transaction involves significant stakeholders, including Reid Hoffman and RA Capital Management, and is expected to bolster Vor Bio’s efforts in advancing its clinical trials for cancer therapies

TipRanks 5 months ago

VOR
+17.21%
Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%

The funds will support clinical trials for VCAR33ALLO and trem-cel therapies in 2025.

GuruFocus.com 5 months ago

VOR
+17.21%
Vor Bio Announces $55.6 Million Private Placement

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025 Extends cash runway through release of updated data from VBP101 and VBP301 trials in 2025 CAMBRIDGE, Mass., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it has entered into a securi

GlobeNewswire 5 months ago

VOR
+17.21%
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, to

GlobeNewswire 5 months ago

VOR
+17.21%
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial Officer CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2024, and provided a corporate update. “We are pleased with our opera

GlobeNewswire 6 months ago

VOR
+17.21%
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company’s President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management,

GlobeNewswire 7 months ago

VOR
+17.21%
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patient

GlobeNewswire 8 months ago

VOR
+17.21%
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

On-track for trem-cel + Mylotarg™ and VCAR33ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update. “We are pleased with the progress we have made with enrollment of both the trem-cel + Mylotarg and VCAR33ALLO clinical trials during the quarter,” said Dr. Robert A

GlobeNewswire 9 months ago

VOR
+17.21%
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,250 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,875 shares of Vor Bio’s common stock to one newly hired employee. The foregoing stock op

GlobeNewswire 9 months ago

VOR
+17.21%

Performance Overview

Return	VOR	S&P 500 (^GSPC)
YTD	-78.89%	+0.92%
1-Year	-82.64%	+12.48%
3-Year	-94.59%	+42.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vor Biopharma Inc. (VOR)

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Biopharma Secures $55.6M for Cancer Therapy Trials

Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Performance Overview